home / stock / rapt / rapt news

RAPT News and Press, RAPT Therapeutics Inc. From 10/20/25

Stock Information
Company Name: RAPT Therapeutics Inc.
Stock Symbol: RAPT
Market: NASDAQ
Website: rapt.com
Menu
RAPT RAPT Quote RAPT Short RAPT News RAPT Articles RAPT Message Board
Get RAPT Alerts

News, Short Squeeze, Breakout and More Instantly...
RAPT - RAPT Therapeutics jumps on mid-stage data for urticaria candidate

2025-10-20 11:03:00 ET More on RAPT Therapeutics Seeking Alpha’s Quant Rating on RAPT Therapeutics Historical earnings data for RAPT Therapeutics Financial information for RAPT Therapeutics Read the full article on Seeking Alpha For further det...
RAPT - FireSuites, Pharma, and FDA Fun

2025-10-20 09:39:00 ET DENVER, Colo., Oct 20, 2025 ( 247marketnews.com )- Wall Street is opening the week with a spotlight on experiential entertainment, oncology breakthroughs, and biopharma advancements, and other tickers are hitting high notes. Live entertainment operator VENU ...

RAPT - RAPT Therapeutics and Shanghai Jeyou Pharmaceutical Announce Positive Topline Data from Phase 2 Trial of RPT904 (JYB1904) in Chronic Spontaneous Urticaria

-  RPT904 at both Q8W and Q12W dosing showed comparable efficacy and safety to omalizumab at Q4W dosing -  Efficacy sustained at Week 16 after a single dose of RPT904 -  Well tolerated with no serious adverse events related to study drug -  Jeyou to advance RPT904 to Pha...

RAPT - RAPT Therapeutics to Report Topline Data from Phase 2 Clinical Trial of RPT904 in Chronic Spontaneous Urticaria (CSU)

SOUTH SAN FRANCISCO, Calif., Oct. 19, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological disease...
RAPT - RAPT Therapeutics Announces FDA Clearance of IND Application to Proceed to Phase 2b Trial of RPT904 in Food Allergy

SOUTH SAN FRANCISCO, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseas...

RAPT - RAPT Therapeutics to Participate in Multiple Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological disease...

RAPT - Expected earnings - RAPT Therapeutics Inc.

RAPT Therapeutics Inc. (RAPT) is expected to report $-0.61 for Q2 2025
RAPT - RAPT Therapeutics GAAP EPS of -$0.65

2025-08-07 09:20:08 ET More on RAPT Therapeutics Seeking Alpha’s Quant Rating on RAPT Therapeutics Historical earnings data for RAPT Therapeutics Financial information for RAPT Therapeutics Read the full article on Seeking Alpha For further det...

RAPT - RAPT Therapeutics Reports Second Quarter 2025 Financial Results

SOUTH SAN FRANCISCO, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT” or the “Company”), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patie...

RAPT - RAPT Therapeutics Names Two Industry Veterans to its Board of Directors

SOUTH SAN FRANCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological disease...
Previous 10 Next 10